Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis clinical studiesPublished : Friday, February 28, 2014
Galapagos NV announced that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and ulcerative colitis. GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos' inflammation alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization.
BAM Utiliteitsbouw will construct the Biotech Training Facility at Leiden Bio Science Park. Yesterday the design and build contract was signed. The contract value is approximately € 5 million. The Biotech Training Facility will be a unique international GMP training facility for employees in the (bio)pharmaceutical industry that will meet the urgent need for highly qualified personnel in the sector.
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, announced it has been granted a European patent on its lead compound ISA101. The patent ensures market protection of ISA101’s active ingredient in Europe until 2028.
Pharming Group NV and Salix Pharmaceuticals, Ltd. announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date to July 16, 2014 for the Company’s Biologics License Application (BLA) for the investigational drug RUCONEST® (recombinant human C1 esterase inhibitor) 50 IU/kg. Pharming and Salix are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
Universal Biotech and its partners are proud to announce that the call for proposal for the 6th edition of the Innovation Prize is now open!
The prize rewards innovative projects in the following fields of Life Sciences: Drug Development, Biotechnology, Medical Devices, Medical Technologies and e-health solutions.
On February 10th at the Naturalis Biodiversity center, the Regio Werktop Leiden took place. The purpose of this summit was to involve specific vulnerable groups, such as people with employment restrictions, better for participating in the labor market. Also, ensuring smooth transitioning of (nearly) graduated students as employees into corporate organizations was an important topic.
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitisPublished : Monday, February 17, 2014
Galapagos NV announced that patient recruitment has been completed for the clinical Proof of Concept study with GLPG0974. GLPG0974 presents a novel mode of action for the treatment of ulcerative colitis, a debilitating inflammatory bowel disease. The efficacy and safety of GLPG0974 are being evaluated during a 28-day treatment period. Topline results from this study are expected in June 2014. GLPG0974 is fully proprietary to Galapagos.
On Monday, 24 March and Tuesday, 25 March 2014 The Hague will be welcoming delegations from more than 50 countries who will be attending the Nuclear Security Summit (NSS). In total 58 world leaders, 5,000 delegates and 3,000 journalists will be coming to the summit at the World Forum. This means that extra traffic measures will be needed and everyone is strongly advised to use public transportation.
As in previous years Rabobank encourages developments and innovations that contribute to a sustainable future. One of this initiatives is the annual presentation of the Herman Wijffels Innovation Award. This year, three prices of € 30,000.- in the categories food & agriculture, circular economy and heath & wellness, can be won.
Registration is open until April 1.
> Read more in Dutch
Galapagos NV announced that it has been awarded a €2.3 million grant for research in fibrosis from the Flemish agency for Innovation by Science and Technology (IWT). The goal of this 2-year project is to create a new research platform by integrating knowledge from a range of fibrotic diseases, including lung, kidney, liver, and skin fibrosis. This new platform will support Galapagos' efforts to develop novel drug candidates in fibrosis.
More and more Chinese companies set up business in The Hague region. Fresh investments from China and the opening of new Chinese subsidiaries are to create 565 jobs in the WestHolland region. The WestHolland Foreign Investment Agency (WFIA), which works on behalf of Municipalities, the Province and the Chamber of Commerce, is responsible for attracting new foreign investments and companies to the region. According to its annual results for 2013, WFIA assisted 42 foreign companies with establishing new offices or relocating, the largest number in its 13-year history.
Galapagos NV announced today that the first clinical centers have been opened for enrolment in the Phase 2 clinical study in Crohn's disease with GLPG0634, a selective JAK1 inhibitor. The Phase 2 study will evaluate the efficacy and safety of GLPG0634 during 20 weeks of treatment in 180 patients with active Crohn's disease.
Nettie Buitelaar announced her decision to terminate her activities for Leiden Bio Science Park, probably around April 1 this year. She wants to focus more on some new biotechnology initiatives, such as the start-up of her own biotech company BiosanaPharma (with three others), which is developing a much more efficient production process for monoclonal antibodies.
ProteoNic BV, a leading provider of technology for recombinant protein production, will participate in an international consortium that has been awarded a EUR 7 million Framework Program 7 (FP7) Research Grant by the European Commission. The FP7 grant will support the development of novel enzymes for efficient production of antioxidants.
HAL Allergy B.V. announced a positive outcome of the dose range finding study with its sublingual immunotherapy product, SUBLIVAC® FIX Birch. In this study, patients with birch pollen induced allergic rhinitis were treated for 5 months with either one of four active doses or placebo. After 5 months of treatment, the primary outcome measure, the composite nasal symptom score following the nasal provocation test, decreased in all active dose groups compared to placebo whereby a clear and significant (p<0.001) dose response relationship was observed.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe